Full agonist

A full agonist is a compound that, on binding to a receptor, produces the largest response that receptor is capable of generating. This maximum response — known as the Emax — is the ceiling for that receptor system, and any compound that reaches it qualifies as a full agonist regardless of how tightly it binds or how much of it is required.

The concept sits within a trio of distinct properties: efficacy (how large a response the drug can produce), affinity (how readily it binds to the receptor), and potency (the concentration needed to achieve a given effect). A full agonist has maximal efficacy by definition. It may, however, have low affinity or low potency — these three properties are independent of one another.

How it works · its role

When a full agonist binds to a receptor, it stabilises that receptor in its fully active conformation — the shape that triggers the downstream signalling cascade most completely. At sufficient concentration, the drug saturates the receptor's capacity to respond.

The contrast is clearest with a partial agonist, which binds the same receptor but stabilises it in an intermediate conformation, producing a submaximal response even when every receptor site is occupied. No matter how much partial agonist is present, the response stays below the full-agonist ceiling. An inverse agonist operates differently still: it actively shifts the receptor toward an inactive state, reducing signalling below resting levels.

Relevance to substances & effects

Full agonism appears across virtually every major receptor class relevant to psychopharmacology. At mu-opioid receptors, compounds including morphine, oxycodone, heroin, and fentanyl are full agonists — they produce pain suppression, euphoria, and respiratory depression that scale with dose and receptor occupancy. This is pharmacologically distinct from buprenorphine, a partial agonist at the same receptor, whose ceiling effect sits well below the full response.

At GABA-A receptors, benzodiazepines act as full agonists at their allosteric binding site, maximising chloride influx through that mechanism. Muscimol, the active compound in Amanita muscaria, is a full agonist at GABA-A's primary orthosteric site — a different point of action, but one producing similarly pronounced sedation and CNS depression.

The designation matters for reading substance pages because it describes the shape of the dose–response curve. Effects driven by full agonism continue scaling with dose without a built-in pharmacological ceiling. Where a partial agonist's ceiling limits worst-case outcomes such as respiratory depression, a full agonist's ceiling is the receptor's own physiological maximum — a limit set by biology, not by the drug.